Freeline Therapeutics Holdings plc
NASDAQ:FRLN
Overview | Financials
Company Name | Freeline Therapeutics Holdings plc |
Symbol | FRLN |
Currency | USD |
Price | 6.49 |
Market Cap | 28,283,096 |
Dividend Yield | 0% |
52-week-range | 2.11 - 8.745 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Michael J. Parini J.D. |
Website | https://www.freeline.life |
An error occurred while fetching data.
About Freeline Therapeutics Holdings plc
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD